| abstract |
This disclosure relates to a method of treating patients with non-radiographic axillary spondyloarthropathy (nr-axSpA) using IL-17 antagonists, such as, for example, Sekuki Napp, and inhibiting the progression of structural damage in these patients. In addition, the use of IL-17 antagonists, such as IL-17 antibodies, such as secukinimum for treating nr-axSpA patients and inhibiting the progression of structural damage in these patients, as well as for use in the disclosed uses and methods Medicaments, administration regimens, pharmaceutical formulations, dosage forms and kits are disclosed herein. |